Brought to you by 
AZ licenses SNG001 antiviral from Synairgen; rights returned
16 May 2017
Executive Summary
Respiratory drug developer Synairgen PLC granted AstraZeneca PLC exclusive global rights to SNG001, an inhaled interferon beta agonist for respiratory infections in patients with asthma and COPD.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Pulmonary
-
Drug Delivery
-
Biotechnology
- Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AZ licenses SNG001 antiviral from Synairgen; rights returned
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice